NCT03573700 2025-11-18
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01807611 2022-10-31
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01319981 2022-09-27
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00671658 2020-12-03
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00857389 2020-04-07
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01010217 2020-03-25
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00968253 2019-02-27
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00578461 2016-04-22
REGKINE
Baylor College of Medicine
Phase NA Terminated
NCT00578539 2016-04-22
REGALE
Baylor College of Medicine
Phase NA Terminated
NCT00038610 2015-09-18
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00941928 2014-05-22
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Terminated